

Τo,

Date: November 29, 2024

The Manager	The Manager,
BSE Limited	National Stock Exchange of India Limited,
P. J. Towers, Dalal Street	Exchange Plaza, Bandra Kurla Complex,
Mumbai-400001	Bandra (E), Mumbai- 400051.
(BSE Scrip Code: 543389)	(NSE Symbol: SIGACHI)

Dear Sir/Madam,

Sub: Press Release- Company received communication from EDQM on CEP filing of Propafenone HCl

Sigachi Industries Limited, a leading player in pharmaceutical industry is pleased to announce about its recent submission of CEP filing for "Propafenone Hydrochloride"

A press release to this extent is enclosed for your information and records.

Thanking you.

Yours Faithfully, For Sigachi Industries Limited

Vivek Kumar Company Secretary & Compliance Officer



Registered Office

#229/1 & 90, 2nd Floor, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad-49, Telangana State, India. Customer Service +91 40 40114874-76, E-mail: info@sigachi.com, URL: www.sigachi.com

Corporate Office

Plot No. G57/2, Industrial Park, Sultanpur, Hyderabad, Sangareddy (Dist), Telangana - 502319. Tel No.: +91-8455-242055 / 56 / 57, E-mail: enquiry@sigachi.com, URL: www.sigachi.com



SIGACHI INDUSTRIES LIMITED

CIN: L24110TG1989PLC009497

Sigachi Industries Limited is pleased to announced that Trimax Biosciences Pvt Ltd, A Sigachi Group Company has received a communication from European Directorate for the Quality of Medicines & Health Care ("EDQM") on its latest CEP Filing submission of "Propafenone Hydrochloride". Achieving the Certificate of Suitability for this API will enable the company to export this product in Europe and other CEP accepting countries.

Friday, 29th November 2024: Sigachi Industries Limited, a leading player in pharmaceutical industry is pleased to announce about its recent submission of CEP filing for "Propafenone Hydrochloride". This is a significant step towards ensuring European regulatory standards and highest levels of product quality and safety. It will also strategically diversify Sigachi's revenue channels to enhance greater value for all stakeholders involved.

- Propafenone Hydrochlride, widely used in the treatment of cardiac arrhythmias, is a highdemand API with a current global market size of USD 1.2 billion.
- The market is poised for robust growth, with projections reaching USD 2.1 billion by 2032, reflecting a CAGR of 7% over the forecast period. This growth is driven by the increasing prevalence of cardiovascular diseases, growing adoption of generic medications, and rising healthcare expenditure globally.
- The company is committed in delivering excellence though advanced manufacturing capabilities and catering needs of highly regulated markets, including the EU ensuring compliance and highest quality standards.

Commenting on this development, Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited stated

"The submission of our first CEP filing is a testament to Trimax Biosciences' commitment to quality, compliance, and innovation in the API domain. This achievement not only strengthens our position in the pharmaceutical supply chain but also aligns with our vision of providing reliable and sustainable pharmaceutical solutions on a global scale."



Registered Office

#229/1 & 90, 2nd Floor, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad-49, Telangana State, India. Customer Service +91 40 40114874-76, E-mail: info@sigachi.com, URL: www.sigachi.com

Corporate Office

Plot No. G57/2, Industrial Park, Sultanpur, Hyderabad, Sangareddy (Dist), Telangana - 502319. Tel No.: +91-8455-242055 / 56 / 57, E-mail: enquiry@sigachi.com, URL: www.sigachi.com



SIGACHI INDUSTRIES LIMITED

CIN: L24110TG1989PLC009497

For further information on the Company, please visit <u>www.sigachi.com</u>

About Trimax Biosciences Pvt Ltd

Founded on May 11, 2010, Trimax Bio Sciences Private Limited is a proud subsidiary of Sigachi Industries Limited, specializing in the development and manufacture of active pharmaceutical ingredients (APIs), intermediates, and advanced intermediates. Located in Raichur, Karnataka, our state-of-the-art facility is designed to meet the highest industry standards, complying with USFDA, cGMP, EMEA, and WHO-GMP guidelines.

At Trimax, we are committed to delivering excellence in every product we create. Our USFDAapproved facility focuses on producing critical and advanced intermediates that play a pivotal role in modern healthcare solutions. By combining cutting-edge technology with rigorous quality assurance, we aim to address the evolving needs of the global pharmaceutical market.

With a strong emphasis on innovation, quality, and compliance, Trimax Bio Sciences is more than a manufacturer—we're a reliable partner in advancing global health.

For further information, please contact:

Mr. Chaitanya Rapol Senior Manager – Marketing ,Branding and Communications Sigachi Industries Limited Email: <u>Chaitanya.rapol@sigachi.com</u>





Registered Office #229/1 & 90, 2nd Floor, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad-49, Telangana State, India. Customer Service +91 40 40114874-76, E-mail: info@sigachi.com, URL: www.sigachi.com

Corporate Office

Plot No. G57/2, Industrial Park, Sultanpur, Hyderabad, Sangareddy (Dist), Telangana - 502319. Tel No.: +91-8455-242055 / 56 / 57, E-mail: enquiry@sigachi.com, URL: www.sigachi.com